Perrigo (NYSE:PRGO) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Perrigo (NYSE:PRGO) from a hold rating to a buy rating in a research note published on Saturday morning.

Several other research firms have also recently issued reports on PRGO. Weiss Ratings raised Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Stock Performance

Perrigo stock opened at $12.83 on Friday. The company has a current ratio of 2.32, a quick ratio of 1.59 and a debt-to-equity ratio of 1.31. The firm has a market cap of $1.78 billion, a P/E ratio of -1.03, a P/E/G ratio of 1.34 and a beta of 0.51. Perrigo has a 1-year low of $9.23 and a 1-year high of $24.60. The firm has a 50-day moving average of $10.62 and a 200-day moving average of $11.54.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.11. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. Perrigo had a positive return on equity of 11.25% and a negative net margin of 41.85%.Perrigo’s revenue was down 3.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.06) EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts expect that Perrigo will post 2.2 EPS for the current year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be given a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 9.0%. The ex-dividend date of this dividend is Friday, August 28th. Perrigo’s dividend payout ratio (DPR) is -9.27%.

Institutional Investors Weigh In On Perrigo

Hedge funds and other institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its holdings in shares of Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares during the last quarter. Geneos Wealth Management Inc. increased its position in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares in the last quarter. UMB Bank n.a. increased its position in Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after buying an additional 1,213 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Perrigo during the fourth quarter valued at $28,000. Finally, CWM LLC raised its stake in Perrigo by 230.0% during the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after buying an additional 1,527 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.